AbCellera Biologics Inc.
ABCL· Nasdaq
Released Feb 20, 2024, after the close
10-K filed Feb 20, 2024, 51 days after period end · 0001703057-24-000019
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $9.18M | $21.54M | $139.31M | $207.91M |
| Net Income | -$47.15M |
AbCellera Biologics Inc. · CIK 1703057 · Engraved from SEC EDGAR
| -$29.89M |
| $59.95M |
| $117.00M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.